2023 Annual Financial Report

Dechra Pharmaceuticals PLC
30 October 2023
 

 

 

30 October 2023

 

 

Dechra® Pharmaceuticals PLC

(the Company)

 

2023 Annual Financial Report

 

 

The Company announced its Preliminary Results on 12 October 2023 in accordance with the financial reporting obligations of the Disclosure and Transparency Rules.

 

Copies of the Annual Financial Report for the year ended 30 June 2023 have today been mailed to shareholders.

 

In accordance with Listing Rule 9.6.1, a copy of the Annual Financial Report has been submitted to the FCA document viewing facility https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

The Annual Financial Report is available to view on the Company's website www.dechra.com.

 

The Notice of Annual General Meeting and information relating to the voting rights of Shareholders (as required by section 311A of the Companies Act 2006) will be distributed to shareholders on 14 November 2023.

 

Further copies of the Annual Report are available from the Company's registered office at:

 

24 Cheshire Avenue

Cheshire Business Park

Lostock Gralam

Northwich

CW9 7UA

 

 

Enquiries:

Melanie Hall, Company Secretary

Dechra Pharmaceuticals PLC

Tel: +44 (0) 1606 814730

 

 

 

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. For more information please visit: www.dechra.com.

 

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings